Universidade do Estado do Rio de Janeiro / Estudos publicados nas duas últimas décadas sugerem um aumento do risco de doença cardiovascular (DCV) em pacientes com periodontite, mas os mecanismos fisiopatológicos dessa associação ainda não estão completamente esclarecidos. Uma vez que foi demonstrado aumento da ativação plaquetária e do estresse oxidativo na periodontite, o objetivo do presente estudo foi investigar a via L-arginina-óxido nítrico (NO)- guanosina monofosfato cíclica (GMPc) e parâmetros de estresse oxidativo em plaquetas de pacientes com periodontite, bem como avaliar o efeito do tratamento periodontal não-cirúrgico nessas variáveis. Um total de 10 pacientes sem periodontite (periodontalmente saudáveis ou com gengivite) e 10 pacientes com periodontite participaram do estudo. A avaliação clínica, laboratorial e experimental foi realizada no início do estudo e 90 dias após realização da terapia periodontal básica (grupo periodontite). A avaliação clínica periodontal incluiu registros de: profundidade de bolsa à sondagem (PBS), nível de inserção (NIC), percentual de placa e percentual de sangramento à sondagem. Os seguintes experimentos foram realizados: influxo de L-arginina; atividade e expressão das enzimas óxido nítrico sintase e da arginase; expressão das enzimas guanilato ciclase solúvel e fosfodiesterase 5; determinação dos níveis intraplaquetários de GMPc; agregação plaquetária; avaliação do estresse oxidativo (atividade oxidante total, atividade das enzimas antioxidantes catalase e da superóxido dismutase - SOD); medição dos níveis de proteína C reativa (CRP) e de fibrinogênio. Os resultados obtidos no início do estudo demonstraram ativação do influxo de L-arginina em plaquetas via sistema y+L nos pacientes com periodontite, bem como concentrações intraplaquetárias de GMPc diminuídas e aumento sistêmico da CRP. Após o tratamento periodontal, observou-se redução do percentual de sítios com PBS ≥ 6 mm, NIC 4-5 mm e NIC ≥ 6 mm, aumento nos níveis de GMPc, para níveis comparáveis aos dos pacientes sem periodontite, acompanhado por uma maior atividade das enzimas antioxidantes SOD e catalase. Os demais parâmetros avaliados não apresentaram alterações significativas tanto pré- quanto pós-tratamento. Esses resultados considerados em conjunto sugerem uma menor biodisponibilidade de NO em plaquetas na periodontite e que o tratamento periodontal não-cirúrgico foi capaz de reverter este quadro por um aumento das defesas antioxidantes. Portanto, alterações na via L-arginina-NO-GMPc e no estresse oxidativo podem levar à disfunção plaquetária, que poderia contribuir para um maior risco de DCV nos pacientes com periodontite. / Studies published over the last two decades have suggested an increase of cardiovascular disease (CVD) risk on periodontitis patients, but the physiopathological mechanisms involved in this association are not yet clear. Since it has been demonstrated an enhancement on both platelet activation and oxidative stress on periodontitis patients, the aim of this study was to investigate the L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway on platelets from periodontitis patients, and the effect of non-surgical periodontal treatment in these variables. A total of 10 patients without periodontitis (periodontal healthy controls or gingivitis patients) and 10 periodontitis patients were included in this study. The clinical, laboratorial, and experimental evaluations were performed at the beginning of the study and 90 days after the basic periodontal therapy (periodontitis group). The clinical periodontal evaluation included the measurements of probing pocket depth (PPD), clinical attachment level (CAL), plaque percentage, and percentage of bleeding on probing. The following experiments were performed: L-arginine influx; nitric oxide synthase and arginase enzymes activity and expression; expression of guanylate cyclase and phosphodiesterase-5 enzymes; measurement of intraplatelet cGMP levels; platelet aggregation; oxidative stress evaluation (total oxidant activity and activity of both antioxidant enzymes catalase and superoxide dismutase SOD); measurement of C reactive protein (CRP) and fibrinogen. The initial results demonstrated an activation of L-arginine influx in platelets from periodontitis patients via y+L system, reduced intraplatelet cGMP levels and increased CRP. After periodontal treatment, it was observed reduction on percentage of sites with PPD ≥ 6 mm, CAL 4-5 mm and CAL ≥ 6 mm, enhancement on cGMP levels, to levels comparables to patients without periodontitis, accompanied by a higher activity of both antioxidant enzymes SOD and catalase. The other evaluated parameters did not showed significant alterations before and after periodontal treatment. The present results suggested a decreased NO biodisponibility in platelets from periodontitis patients and that the non-surgical periodontal treatment was effective to revert this condition, due to an enhancement on antioxidant defence. Therefore, alterations on L-arginine-NO-cGMP pathway and oxidative stress may lead to platelet dysfunction, which could contribute to a higher risk of CVD in periodontitis patients.

O óxido nítrico (NO) é um mensageiro químico gerado pela atividade da enzima óxido nítrico sintase (NOS) a qual foi detectada em vários órgãos incluídos os do sistema reprodutor e parece estar envolvido na maturação oocitária. No entanto, há poucos estudos sobre o papel desse sistema em oócitos da espécie bovina. Sabe-se que o NO atua pela via da guanilato ciclase (GC) estimulando a produção do nucleotídeo GMPc, que por sua vez é capaz de influenciar nos níveis de outro nucleotídeo (AMPc) via fosfodiesterases (PDE). O AMPc é um importante elemento da via de sinalização do FSH nos complexos cumulus-oócitos e no controle da maturação oocitária. O objetivo do presente projeto foi investigar a influência do FSH na via do NOS/NO e seus componentes em oócitos bovinos maturados in vitro e o envolvimento das células do cumulus (CC) na via de sinalização. Para tanto, complexos cumulus-oócito (CCO) e oócitos desnudos (OD - maturados sem células do cumulus) foram maturados in vitro por 24h na presença ou ausência de FSH. As amostras foram avaliadas quanto a: 1) taxa da maturação nuclear; 2) níveis de produção de NO; 3) níveis de AMPc e GMPc; 4) abundância relativa de RNAm de NOS2, PDE5A, PDE6C, PKG1, PKG2, ADCY6, ADCY9, PDE3A e PKA1. O FSH, na concentração de 0,05UI/mL, estimulou positivamente a maturação nuclear em CCO e OD, com 80,6 e 89% de oócitos maturados, respectivamente. Quando comparados diretamente os grupos CCO e OD, o FSH não influenciou as taxas de maturação (71 e 71,3%, p>0,05), nem os níveis de produção de NO (12,8 e 7,4 µM/mL, p>0,05). Os níveis de GMPc em CCO aumentaram após 1 e 3 h de MIV na presença de FSH (266,3 e 187,2 pmol/pool com FSH e 240,5 e 168,5 pmol/pool sem FSH, respectivamente, p<0,05). Após 6 h os níveis de GMPc declinaram de forma mais acentuada no grupo sem FSH (46,3 e 106,9 pmol/pool, com e sem FSH, respectivamente, p<0,05). Os níveis de AMPc em CCO também foram mais elevados na presença de FSH à 1 e 3 h de MIV (7,60 e 7,81 pmol/pool, respectivamente) em comparação com CCO maturados sem FSH (0.30 e 0,76 pmol/pool, respectivamente, p<0,05). Após 6h, os níveis declinaram e foram similares para ambos os grupos (0,43 pmol/pool, p>0,05). Em relação à expressão dos genes selecionados, todos foram detectados nos oócitos (CCO e OD), porém, em células do cumulus, foram detectados apenas PDE5A, ADCY6, ADCY9 e PKA1. Quando observados os resultados do grupo CCO, apenas os genes PKG1, ADCY6 e PDE3A sofreram influência do FSH (p<0,05), apresentando um aumento destes transcritos. No grupo OD, apenas o gene PKG1 sofreu influência do FSH, também apresentando um aumento destes transcritos (p<0,05). Em células do cumulus, os genes ADCY6 e ADCY9 sofreram influência do FSH, sendo que para a ADCY6 provocou um aumentos destes transcritos, e para a ADCY9 provocou uma queda dos mesmos (p<0,05). Em conclusão, o FSH pode exercer influência positiva na maturação nuclear de oócitos bovinos, agindo sobre os níveis de GMPc e AMPc, mas não sobre o NO. O FSH pode influenciar a expressão gênica em oócitos e em células do cumulus de bovinos. / Nitric oxide (NO) is a chemical messenger generated by the nitric oxide synthase (NOS) enzyme, which was detected in several organs including the reproductive system and appears too involved in oocyte maturation. However, there are few studies on the role of this system in bovine oocytes. NO is known to act via guanylate cyclase (GC) stimulating the production of the nucleotide cGMP, which in turn is capable of influencing the levels of another nucleotide, cAMP via phosphodiesterases (PDE). cAMP is an important factor in FSH signaling in cumulus-oocyte complexes (COC) for the control of maturation. The aim of the present work was to investigate the influence of FSH on the NOS/NO pathway and its components in bovine oocytes matured in vitro and the involvement of cumulus cells (CC) in the signaling pathway. COC and denuded oocytes (DO - matured without cumulus cells) were matured in vitro for 24 h with or without FSH. Samples were assessed for: 1) maturation rate; 2) levels of NO production; 3) levels of cGMP and cAMP; 4) relative abundance for mRNA of NOS2, PDE5A, PDE6C, PKG1, PKG2, ADCY6, ADCY9, PDE3A and PKA1. FSH positively stimulated oocyte maturation at 0.05UI/mL concentration for both COC and OD (80.6 and 89% maturation rates, respectively). When COC and OD were compared directly, FSH did not affect maturation rates (71 and 71.3%, p>0.05) nor NO production levels (12,8 and 7,4 µM/mL), p>0.05). cGMP levels increased after 1 and 3 h in vitro maturation (IVM) with FSH (266.3 and 187.2 pmol/pool with FSH and 240.5 and 168.5 pmol/pool without FSH, respectively, p<0.05). After 6 h IVM, cGMP levels in COC declined more in the group cultured with FSH (46.3 and 106.9 pmol/pool, with and without FSH, respectively, p<0.05). cAMP levels in COC were also increased in the presence of FSH at 1 and 3 h IVM (7.60 and 7.81 pmol/pool, respectively) in comparison to COC cultured without the hormone (0.30 and 0.76 pmol/pool, respectively, p<0.05). After 6 h, the levels declined and were similar for both groups (0.43 and 0.02 pmol/pool, p>0.05). Regarding mRNA expression for the selected genes, all of them were detected in oocytes, but only four of them were detected in cumulus cells: PDE5A, ADCY6, ADCY9 and PKA1. For COC only PKG1, ADCY6 and PDE3A were influenced by FSH (p<0.05), with an increase in transcript relative abundance, For DO, only PKG1 was influenced by FSH and also showed an increase in these transcripts (p<0.05). In cumulus cells, ADCY6 and ADCY9 were affected by FSH, with an increase for ADCY6 and a decrease in ADCY9 transcripts (p<0.05). In conclusion, FSH may positively influence nuclear maturation, acting on cGMP and cAMP levels, but not on NO. FSH may also influence gene expression in bovine oocytes and cumulus cells.

Les deux nucléotides cycliques, AMPc et GMPc, sont des seconds messagers importants qui régulent une grande variété de fonctions cellulaires, en particulier la fonction contractile cardiovasculaire, la croissance des cardiomyocytaires et la prolifération des cellules musculaires lisses vasculaires. Les phosphodiestérases (PDE) dégradent les nucléotides cycliques et exercent un contrôle local de leur concentration intracellulaire. Une altération de la voie de signalisation des nucléotides cycliques est impliquée dans plusieurs situations pathologiques telles que l’hypertension artérielle systémique ou pulmonaire, l’athérosclérose et l'hypertrophie cardiaque. Ainsi, les PDE constituent de puissantes cibles thérapeutiques pour restaurer un contrôle correct des nucléotides cycliques. Onze familles de PDEs sont actuellement décrites, les PDE1-6 étant les plus étudiées et les PDE 7-11 représentant de nouvelles familles.L'objectif de cette thèse était d'étudier le rôle respectif de 4 familles de PDEs, la PDE1, famille stimulée par le complexe Ca2+/calmoduline, les PDE5 et PDE9 spécifiques du GMPc, et la PDE8 spécifique de l'AMPc, dans le contrôle des concentrations intracellulaires d'AMPc ([AMPc]i) et de GMPc ([GMPc]i) dans les cellules musculaires lisses aortiques de rat (CMLARs) et les myocytes cardiaques de rat en utilisant une approche pharmacologique facilitée par le développement de nouveaux inhibiteurs sélectifs de PDEs. Les activités d'hydrolyse d’AMPc et de GMPc ont été mesurées par dosage enzymatique, tandis que les [AMPc]i et [GMPc]i ont été suivies sur cellules isolées, in situ, en temps réel, grâce à l'utilisation de l'imagerie FRET (Fluorescence Resonance Energy Transfer). Dans les CMLARs en culture, une activité d'hydrolyse des nucléotides cycliques via les PDE1, PDE5 et PDE9 a été observée. Nous avons montré un rôle fonctionnel de la PDE1 non stimulée dans le contrôle de l’augmentation de la [GMPc]i induite par le peptide natriurétique de type C (CNP). Il est intéressant de noter que, lors de l’élévation de la concentration intracellulaire en Ca2+, la PDE1 exerce également un contrôle de la réponse GMPci induite par le monoxyde d’azote (NO) et de la réponse AMPc médiée par la stimulation des récepteurs β-adrénergiques (β-AR). La PDE5 exerce un rôle majeur dans la réponse GMPc provoquée par l'activation de la guanylyl cyclase (GC) soluble par le NO ou des GC membranaires par les peptides natriurétiques, CNP et ANP. En revanche, la PDE9 ne régule que la réponse GMPc induite par le NO dans les RASMC cultivées. Aucune activité ou fonction hydrolytique de l'AMPc n'a été révélée avec l'inhibiteur de la PDE8 dans les CMLARs ou les cardiomyocytes de rat. Dans ces cellules cardiaques, l'activité d'hydrolyse médiée par la PDE1 n'a été détectée que sur la réponse GMPc et uniquement en présence de Ca2 +/Calmoduline. L'inhibiteur de la PDE1 n'a que légèrement affecté la réponse AMPc médiée par les récepteurs β-AR, par augmentation du pic du signal FRET.En conclusion, notre travail démontre que dans les cellules musculaires lisses vasculaires, les PDE1, PDE5 et PDE9 exercent une régulation spécifique et locale des [AMPc]i et [GMPc]i, renforçant le rôle clé des PDEs dans la compartimentation subcellulaire de la signalisation des nucléotides cycliques. / The two cyclic nucleotides cAMP and cGMP are important second messengers that regulate a large variety of cellular functions, in particular cardiovascular contractile function, cardiomyocyte cell growth and vascular smooth muscle cell proliferation. Phosphodiesterases (PDEs) degrade cyclic nucleotides, and exert a fine local control of their intracellular concentration. Alteration of cyclic nucleotides signaling pathway is involved in several pathological situations such as systemic and pulmonary arterial hypertensions, atherosclerotic lesions and cardiac hypertrophy. Thus, PDEs constitute potent therapeutic targets to restore a right cyclic nucleotide function. Eleven families of PDEs are now described, PDE1-6 being the most studied and PDE 7-11 representing the new families.The aim of the present thesis was to investigate the respective role of 4 PDE families, the Ca2+/calmodulin-stimulated PDE1, the cGMP-specific PDE5 and PDE9, and the cAMP-specific PDE8, in controlling intracellular cAMP ([cAMP]i) and intracellular cGMP ([cGMP]i) concentrations in both rat aortic smooth muscle cells (RASMCs) and cardiac myocytes by using a pharmacological approach taken advantage of the development of new selective PDE inhibitors. Cyclic AMP- and cGMP-hydrolyzing activities were measured by enzymatic assay on cell lysate, whereas real-time [cAMP]i and [cGMP]i were followed in situ in isolated cells using Fluorescence Resonance Energy Transfer (FRET) imaging. In cultured RASMCs, PDE1, PDE5 and PDE9 hydrolyzing activities were observed. We showed a functional role of basal PDE1 in controlling [cGMP]i increased by the C-type Natriuretic Peptide (CNP). Interestingly, upon high intracellular Ca2+ concentration, PDE1 also regulated the Nitric Oxide (NO)-mediated [cGMP]i response and the β-adrenoceptor (β-AR)-mediated [cAMP]i response. PDE5 exerted a major role in degrading [cGMP]i produced by the activation of either the soluble guanylyl cyclase (GC) elicited by NO or the particulate GCs by the natriuretic peptides, CNP and ANP. By contrast, PDE9 only regulated NO-induced [cGMP]i increase in cultured RASMCs. No cAMP-hydrolyzing activity or function was revealed with the PDE8 inhibitor in RASMCs or cardiac myocytes. In rat cardiomyocytes, PDE1-mediated hydrolyzing activity was only detected on cGMP in the presence of Ca2+/calmodulin. Unexpectedly, PDE1 inhibition slightly affected the β-AR-mediated [cAMP]i response by increasing the peak of FRET signal.In conclusion, our work underscores the distinct role of PDE1, PDE5, and PDE9 in locally regulating the [cAMP]i and [cGMP]i, in vascular smooth muscle cells, strengthening the concept of PDEs as key actors of cyclic nucleotide subcellular compartmentation.

Phosphodiesterase Type 5 (PDE5) inhibitors are cardioprotective against ischemia/reperfusion (I/R) injury. However, it remains uncertain if I/R affects PDE5. We hypothesized that generation of reactive oxygen species (ROS) during I/R leads to upregulation of PDE5, which contributes to pathological changes following acute myocardial infarction (AMI). Adult male ICR mice were subjected to 30 minutes of in vivo or ex vivo I/R. To examine the role of ROS, a subset of hearts were perfused with 100 µM hydrogen peroxide (H2O2). Expression and activity of PDE5, pPDE5, and cGMP-dependent protein kinase (PKG) were measured by Western blots and spectrophotometric assay. The results show that ischemia and I/R significantly increased expression of PDE5. H2O2 had no effect on PDE5 expression and activity but significantly increased PKG activity. We conclude that acute cardiac ischemia or I/R upregulate PDE5 independent of oxidant stress in the heart.

In vitro, meotic maturation of porcine oocytes and cumulus expansion are induced by FSH and EGF-like peptides AREG and EREG. FSH and EGF-like peptides induce expression of cumulus expansion-related genes (HAS2, PTGS2 and TNFAIP6). To define signaling pathways that control FSH- and AREG-induced cumulus expansion, porcine cumulus-oocyte complexes were treated with specific protein kinase inhibitors. Inhibitors of MAPK3/1, MAPK14 and ERBB1 significantly reduced both FSH- and AREG-induced expression of HAS2, PTGS2 and TNFAIP6. These inhibitors decreased FSH/LH-induced expression of AREG and EREG in mural granulosa cells. Surprisingly, inhibitor of PKA had no effect on AREG expression in cumulus-oocyte complexes but the inhibitor decreased expression of TNFAIP6 induced by AREG. Inhibitor of PI3K increased expression levels of AREG and PTGS2 but EREG, HAS2 and TNFAIP6 were reduced. Expression levels of the cumulus expansion-related genes were not affected by an analog of cGMP (8-CPT-cGMP). However, 8-CPT-cGMP blocked spontaneous in vitro meiotic maturation of porcine oocytes and its effect was abolished by FSH. Key words: cumulus expansion, cumulus expansion-related genes, meotic maturation, FSH, amphiregulin, cGMP

A diminuição da biodisponibilidade do óxido nítrico (NO) e o aumento na atividade das metaloproteinases da matriz extracelular (MMPs) são alguns dos principais mecanismos fisiopatogênicos envolvidos nas doenças cardiovasculares (DCV). Foi demonstrado que o NO pode reduzir a expressão e atividade de MMPs em células musculares lisas vasculares, células mesangiais, entre outras. Em outro estudo, foi mostrado que drogas inibidoras da NO sintase (NOS) podem aumentar a expressão de MMPs. Apesar de o NO apresentar-se diminuído e as MMPs aumentadas durante as DCV, não há evidência clara de que os níveis de NO possam modular diretamente a atividade de MMPs no aparelho cardiovascular. Também não se sabe se este possível efeito seria mediado pelo NFB, nem se este possível efeito é dependente da ativação da guanilato ciclase [que promove a formação de GMP cíclico (GMPc)]. Desta maneira, este estudo teve como objetivos: A) investigar os efeitos de drogas ativadoras da via NO-GMP sobre os aumentos da atividade e expressão de MMP-9 em células endoteliais que acontecem sob efeito de phorbol 12-miristato 13-acetato (PMA, droga indutora da expressão de MMP-9); e B) determinar se a inibição de NOS em células endoteliais é acompanhada por aumento da atividade e expressão de MMPs, e C) determinar se estes efeitos são dependentes da ativação de NFB ou da formação de GMPc. Células endoteliais de veia umbilical humana (HUVECs) foram cultivadas em DMEM e tratadas por 24 horas com 10 nmol/L de PMA ou diferentes concentrações de drogas ativadoras da via NO-GMP ou de inibidor da NOS. Meio de cultura condicionado ou lisado celular foram coletados e submentidos aos ensaios de zimografia, ELISA, immunoblotting ou análise da concentração de nitrito. Os tratamentos com detanonoato, SNAP, atorvastatina e nitrito de sódio diminuíram os aumentos da atividade gelatinolítica e expressão de MMP-9 estimulados por PMA sem afetar as concentrações do inibidor tecidual da metaloproteinase da matriz-1 (TIMP-1). Esses efeitos não foram modificados pelos tratamentos com ODQ (inibidor da guanilato ciclase solúvel) ou 8- bromo-cGMP (um análogo de GMPc) ou hemoglobina (um sequestrador de NO). Enquanto o PMA aumentou a concentração de fosfo-NFB p65, os tratamentos com SNAP, atorvastatina ou nitrito não apresentaram influência sobre esse efeito. O tratamento com L-NAME, um inibidor da NOS, não apresentou efeito sobre a atividade gelatinolítica de MMP-9. Em conclusão, foram demonstrados que os efeitos inibitórios de drogas ativadoras da via NO-GMPc sobre a produção estimulada de MMP-9 em células endoteliais são independentes de mecanismos mediados por GMPc e NFB, e a inibição da NOS não altera a atividade de MMP-9. / Impaired nitric oxide (NO) bioavailability and imbalanced matrix metalloproteinases (MMPs) activity have important roles in the pathophysiological mechanisms involved in cardiovascular disease (CVD). It was shown that NO can reduce MMPs expression and activity in vascular smooth muscle cells, mesangial cells, and others. In another study, a NO synthase (NOS) inhibitor has increased MMPs expression. Although NO was decreased and MMPs was increased during CVD, there is clear evidence that NO levels can directly modulate MMPs activity in the cardiovascular system. Also, it is not known whether this effect would be mediated by NFB, nor whether this effect is dependent on guanylate cyclase activity (which promotes the formation of cyclic GMP). Thus, this project aims to study whether A) the effect of NO donors might decrease MMP-9 activity and expression in endothelial cells stimulated by phorbol 12-myristate 13-acetate (PMA) (a well-known inducer of MMP-9), and B) the effect of NOS inhibitors might increase MMPs activity and expression in endothelial cells, and C) to determine whether those effects are mediated by the NFB activation or cGMP levels. Endothelial cells from human umbilical vein (HUVECs) were grown in modified DMEM and were treated for 24 hours with 10 nmol/L PMA or different concentrations of NO-GMPc pathway stimulating drugs or NOS inhibitor. Conditioned medium or cell lysate were collected after treatments and analyzed by zymography, ELISA, immunoblotting or to determine nitrite concentration. Detanonoate, SNAP, atorvastatin or sodium nitrite treatments attenuated PMA-induced increases in MMP- 9 gelatinolytic activity and expression, but they had no effect on tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) concentrations. These effects were not modified by ODQ (a soluble guanylate cyclase inhibitor), or 8-bromo-cGMP (cGMP analogue), or hemoglobin (a NO scavenger). While PMA increased phospho-NFB p65 concentration, SNAP, atorvastatin or nitrite had no influence on this effect. The treatment with L-Name, a NOS inhibitor, had no effect on MMP-9 activity. In conclusion, this study shows that the inhibitory effects of NO-GMPc pathway stimulating drugs on MMP-9 production by endothelial cells are independent of cGMP- and NFB-mediated mechanisms, and NOS inhibitor had no effect on MMP-9 levels

Genetisch kodierte Photorezeptoren in Modellorganismen begründen die Optogenetik. Sie ermöglicht die nicht-invasive, reversible und räumlich-zeitlich präzise Perturbation von zellulären und physiologischen Signalprozessen durch Licht. Natürliche photoaktivierte Adenylylzyklasen (PACs) steigern die intrazelluläre Konzentration des Botenstoffs zyklischen Adenosinmonophosphats (cAMP) durch Blaulicht. Damit erlauben sie die optogenetische Analyse von cAMP-abhängigen Signalwegen. Diese Arbeit komplementiert PACs durch die synthetische rotlichtaktivierte Phosphodiesterase LAPD zur Degradation von cAMP und zyklischem Guanosinmonophosphat (cGMP). LAPD ist eine Chimäre aus dem photosensorischen Modul von Deinococcus radiodurans Bakteriophytochrom (DrBPhy) und der Effektordomäne der cAMP/cGMP-spezifischen H. sapiens Phosphodiesterase 2A (HsPDE2A). Die Fusionsstelle wurde von den helikalen Linkern zwischen Sensor- und Effektormodulen durch strukturelle Überlagerung abgeleitet. LAPD inkorporierte den Chromophor Biliverdin (BV) nach Expression in E. coli und Reinigung vollständig und entsprach spektral und photochemisch dem Wildtyp-DrBPhy. Durch Bestrahlung mit Rot- und Fernrotlicht (R bzw. FR) wurde LAPD in die metastabilen photochemischen Zustände Pfr (fernrot) bzw. Pr (rot) umgewandelt. Vollständig aktivierte LAPD katalysierte die Hydrolyse von cGMP und cAMP in derselben Größenordnung wie Wildtyp-HsPDE2A. LAPD degradierte cGMP und cAMP bei 6- bzw. 4-facher Steigerung von vmax unter R im Vergleich zu dunkeladaptiertem Enzym. Die Aktivität von R-adaptierter LAPD wurde durch FR reduziert. Die enzymatische Aktivität und Lichtregulation von LAPD-Linkervarianten waren abhängig von der Linkerlänge. LAPD degradierte lichtabhängig cGMP in einer PDE-Reporterzelle. Dabei genügte die endogene BV-Konzentration der Säugerzelle zur Sättigung des Lichteffekts. / Genetically encoded photoreceptors in model organisms establish optogenetics. It enables non-invasive, reversible, and spatio-temporally precise perturbation of cellular and physiological signalling by light. Natural photoactivated adenylate cyclases (PACs) increase the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP) under blue light. Hence, PACs allow the optogenetic analysis of cAMP-dependent signalling. This work complements PACs with the synthetic red-light-activated phosphodiesterase LAPD for degradation of cAMP and cyclic guanosine monophosphate (cGMP). LAPD is a chimera made up of the photosensory module of Deinococcus radiodurans bacteriophytochrome (DrBPhy) and the effector domain of cAMP/cGMP-specific H. sapiens Phosphodiesterase 2A (HsPDE2A). The fusion site was derived from the helical linkers between sensor and effector modules via structural superposition. LAPD incorporated the chromophor biliverdin (BV) after expression in E. coli and purification quantitatively, and spectrally and photochemically resembled the wildtype DrBPhy. Upon irradiation with red and far-red light (R and FR, resp.), LAPD was converted to the metastable photochemical states Pfr (far-red) and Pr (red), respectively. Fully activated LAPD catalized the hydrolysis of cGMP and cAMP with rates similar to wildtype HsPDE2A. LAPD degraded cGMP and cAMP with 6- and 4-fold increase of vmax under R, respectively, as compared to the dark state. The activity of R-adapted LAPD was reduced upon irradiation with FR. Enzymatic activity and light regulation of LAPD linker variants depended on the linker length. LAPD light-dependently degraded cGMP in a PDE reporter cell line. Endogenous BV concentrations were sufficient to saturate the light effect in the mammalian cell, which enables a true optogenetic approach.

A exposição de animais a situações ameaçadoras de natureza inata ou aprendida resulta em exibição de um repertório de comportamentos defensivos espécie-específicos, alterações autonômicas e em inibição da dor, sendo esse conjunto de reações de alta relevância para a sobrevivência de uma espécie. Considerando este contexto, um importante componente da resposta do organismo a situações de emergência é a redução da capacidade de perceber a dor. O processamento de estímulos nociceptivos pode ser modulado no prosencéfalo, na medula espinal, no tronco encefálico e no diencéfalo, por mecanismos envolvendo diferentes neurotransmissores e neuromoduladores. Nos últimos anos, evidências têm demonstrado que o monóxido de carbono (CO), produzido a partir da enzima heme-oxigenase estimula a formação de guanosina 3, 5- monofosfato cíclico (GMPc), participando como neuromodulador de vários processos fisiológicos. Dentro deste contexto, mostrou-se que a via HO-CO-GMPc está envolvida na modulação periférica e espinal da dor inflamatória, bem como na modulação do estresse, porém não há conhecimento da participação desta via na modulação de estímulo doloroso agudo, bem como da antinocicepção induzida pelo estresse. Assim, este trabalho teve como objetivo avaliar o envolvimento da via HO-CO-GMPc na nocicepção e na antinocicepção induzida pelo estresse agudo em ratos, avaliada pelo índice de analgesia no teste de retirada da cauda (IARC). Nossos resultados demonstraram que a ativação da via HO-CO-GMPc por meio da administração ICV de heme-lisinato (substrato) tem efeito antinociceptivo, sendo este efeito dependente da atividade GMPc, desde que o pré-tratamento com inibidor da guanilase ciclase solúvel (GCs), ODQ, bloqueou o aumento do IARC. Ainda, esta modulação ocorre de maneira fásica e não tônica, pois o tratamento isolado ICV com o inibidor da HO, ZnDBPG ou com o inibidor da GCs, ODQ, não alterou o IARC. A antinocicepção induzida pelo estresse agudo (restrição física por 120 min) não é dependente da via HO-CO-GMPc, desde que o tratamento com o ZnDBPG, nem com o heme-lisinato alteraram o IARC. No entanto, esta antinocicepção é dependente da atividade do GMPc, pois o pré-tratamento com ODQ bloqueou o aumento do IARC. / The exposure of animals to threatening situations of innate or learned nature results in exhibition of a repertoire of species-specific defensive behaviors, autonomic alterations and pain inhibition. This group of reactions has high relevance for the survival of species. In this context, an important component of the response of the organism in the emergency situations is the reduction of the capacity to perceive pain. The processing of nociceptive stimulus can be modulated in forebrain, in spinal, and in midbrain, for mechanisms involving different neurotransmitters and neuromodulators. Recently, evidence has demonstrated that carbon monoxide gas (CO), produced from the enzyme heme oxygenase (HO), stimulate the formation of 3\', 5\' - cyclic guanosine monophosphate (cGMP), and this molecule has participated as neuromodulator in some physiological processes. In this way, it has shown that the HO-CO-cGMP pathway is involved in the peripheral and spinal modulation of inflammatory pain, as well as in the modulation of the stress. However, the involvement of this pathway in the modulation of acute painful stimulus, as well as in the antinociception induced by stress isn´t clarified. Thus, this study evaluated the involvement of the HO-CO-cGMP pathway in nociception and in antinociception induced by acute stress in rats, by means the of analgesia index in the tail flick test (AITF). Our results demonstrated that the activation of the HO-CO-cGMP pathway by means of heme-lysinate ICV administration has antinociceptive effect. Again, the increase of the AITF was dependent of the cGMP activity, since that the pretreatment with inhibitor of soluble guanylase cyclase (sGC), ODQ, blocked the antinociceptive effect. This modulation occurs in fasic and not tonic manner, because per se ICV treatment with inhibitor of the HO, ZnDBPG or with inhibitor of the sGC, ODQ did not modify the AITF. The antinociception induced by acute stress (physical restriction during 120 min) is not dependent of the HO-CO-cGMP pathway, since that neither the treatment with the ZnDBPG, nor with the heme-lysinate had modified the AITF. However, this antinociception is dependent of the activity of the cGMP, because the pretreatment with ODQ blocked the increase of the AITF induced by acute stress.

A diminuição da biodisponibilidade do óxido nítrico (NO) e o aumento na atividade das metaloproteinases da matriz extracelular (MMPs) são alguns dos principais mecanismos fisiopatogênicos envolvidos nas doenças cardiovasculares (DCV). Foi demonstrado que o NO pode reduzir a expressão e atividade de MMPs em células musculares lisas vasculares, células mesangiais, entre outras. Em outro estudo, foi mostrado que drogas inibidoras da NO sintase (NOS) podem aumentar a expressão de MMPs. Apesar de o NO apresentar-se diminuído e as MMPs aumentadas durante as DCV, não há evidência clara de que os níveis de NO possam modular diretamente a atividade de MMPs no aparelho cardiovascular. Também não se sabe se este possível efeito seria mediado pelo NFB, nem se este possível efeito é dependente da ativação da guanilato ciclase [que promove a formação de GMP cíclico (GMPc)]. Desta maneira, este estudo teve como objetivos: A) investigar os efeitos de drogas ativadoras da via NO-GMP sobre os aumentos da atividade e expressão de MMP-9 em células endoteliais que acontecem sob efeito de phorbol 12-miristato 13-acetato (PMA, droga indutora da expressão de MMP-9); e B) determinar se a inibição de NOS em células endoteliais é acompanhada por aumento da atividade e expressão de MMPs, e C) determinar se estes efeitos são dependentes da ativação de NFB ou da formação de GMPc. Células endoteliais de veia umbilical humana (HUVECs) foram cultivadas em DMEM e tratadas por 24 horas com 10 nmol/L de PMA ou diferentes concentrações de drogas ativadoras da via NO-GMP ou de inibidor da NOS. Meio de cultura condicionado ou lisado celular foram coletados e submentidos aos ensaios de zimografia, ELISA, immunoblotting ou análise da concentração de nitrito. Os tratamentos com detanonoato, SNAP, atorvastatina e nitrito de sódio diminuíram os aumentos da atividade gelatinolítica e expressão de MMP-9 estimulados por PMA sem afetar as concentrações do inibidor tecidual da metaloproteinase da matriz-1 (TIMP-1). Esses efeitos não foram modificados pelos tratamentos com ODQ (inibidor da guanilato ciclase solúvel) ou 8- bromo-cGMP (um análogo de GMPc) ou hemoglobina (um sequestrador de NO). Enquanto o PMA aumentou a concentração de fosfo-NFB p65, os tratamentos com SNAP, atorvastatina ou nitrito não apresentaram influência sobre esse efeito. O tratamento com L-NAME, um inibidor da NOS, não apresentou efeito sobre a atividade gelatinolítica de MMP-9. Em conclusão, foram demonstrados que os efeitos inibitórios de drogas ativadoras da via NO-GMPc sobre a produção estimulada de MMP-9 em células endoteliais são independentes de mecanismos mediados por GMPc e NFB, e a inibição da NOS não altera a atividade de MMP-9. / Impaired nitric oxide (NO) bioavailability and imbalanced matrix metalloproteinases (MMPs) activity have important roles in the pathophysiological mechanisms involved in cardiovascular disease (CVD). It was shown that NO can reduce MMPs expression and activity in vascular smooth muscle cells, mesangial cells, and others. In another study, a NO synthase (NOS) inhibitor has increased MMPs expression. Although NO was decreased and MMPs was increased during CVD, there is clear evidence that NO levels can directly modulate MMPs activity in the cardiovascular system. Also, it is not known whether this effect would be mediated by NFB, nor whether this effect is dependent on guanylate cyclase activity (which promotes the formation of cyclic GMP). Thus, this project aims to study whether A) the effect of NO donors might decrease MMP-9 activity and expression in endothelial cells stimulated by phorbol 12-myristate 13-acetate (PMA) (a well-known inducer of MMP-9), and B) the effect of NOS inhibitors might increase MMPs activity and expression in endothelial cells, and C) to determine whether those effects are mediated by the NFB activation or cGMP levels. Endothelial cells from human umbilical vein (HUVECs) were grown in modified DMEM and were treated for 24 hours with 10 nmol/L PMA or different concentrations of NO-GMPc pathway stimulating drugs or NOS inhibitor. Conditioned medium or cell lysate were collected after treatments and analyzed by zymography, ELISA, immunoblotting or to determine nitrite concentration. Detanonoate, SNAP, atorvastatin or sodium nitrite treatments attenuated PMA-induced increases in MMP- 9 gelatinolytic activity and expression, but they had no effect on tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) concentrations. These effects were not modified by ODQ (a soluble guanylate cyclase inhibitor), or 8-bromo-cGMP (cGMP analogue), or hemoglobin (a NO scavenger). While PMA increased phospho-NFB p65 concentration, SNAP, atorvastatin or nitrite had no influence on this effect. The treatment with L-Name, a NOS inhibitor, had no effect on MMP-9 activity. In conclusion, this study shows that the inhibitory effects of NO-GMPc pathway stimulating drugs on MMP-9 production by endothelial cells are independent of cGMP- and NFB-mediated mechanisms, and NOS inhibitor had no effect on MMP-9 levels

In the first 3 years of the Obama Administration, 2009-2011, the number of warning letters issued to pharmaceutical firms for manufacturing and quality issues increased by 81% to 49 letters. Only 9 letters were issued in the last 3 years of the George W. Bush Administration. Shortfalls in compliance and product quality led to medicine shortages that affected patients' treatment and health. This quantitative study sought to learn to what extent, if any, the independent variables, management behaviors and financial indicators at pharmaceutical firms in the United States, correlated with, or predicted, the dependent variable, compliance with the FDA regulations. FDA's enforcement actions on the firms were the treatment event. A shift in the relationship between the variables occurred after the FDA interventions, which highlighted a new level of compliance. Of the 1144 SurveyMonkey invitations sent to the members of the International Society of Pharmaceutical Engineers, only 21 completed the survey's 133 questions. Three research questions were addressed using correlations and linear regressions. The theory of planned behavior was applied to correlate behavioral constructs with the compliance of the firms leading to the rejection of the null hypothesis. By establishing an inverse relation between financial indicators and the firms' level of compliance, the study offers awareness and insight to senior leaders regarding their behaviors and the decision-making process. Enhancing managers' decision-making processes in light of their beliefs, along with their control over financial indicators, could reinforce the presence of effective quality systems among pharmaceutical manufacturers minimizing medicine shortages.